The Influence of Synthetic Cannabinoid UR-144 on Human Psychomotor Performance—A Case Report Demonstrating Road Traffic Risks

Traffic Injury Prevention

Volumn 16, Issue 8, 2015, Pages 754-759

  Adamowicz, Piotr ^a   Lechowicz, Wojciech ^a  

^a INSTITUTE OF FORENSIC RESEARCH   (Poland)

Author keywords

analysis; driving under the influence of drugs (DUID); LC MS MS; synthetic cannabinoids; UR 144

Indexed keywords

(1-PENTYL-1H-INDOL-3-YL)(2,2,3,3-TETRAMETHYLCYCLOPROPYL)METHANONE; CANNABINOID; DESIGNER DRUG; DRONABINOL; INDOLE DERIVATIVE;

BLOOD; CAR DRIVING; DRUG EFFECTS; HUMAN; LIQUID CHROMATOGRAPHY; MALE; PSYCHOLOGY; PSYCHOMOTOR PERFORMANCE; RISK; STATISTICS AND NUMERICAL DATA; TANDEM MASS SPECTROMETRY; TRAFFIC ACCIDENT; YOUNG ADULT;

ACCIDENTS, TRAFFIC; AUTOMOBILE DRIVING; CANNABINOIDS; CHROMATOGRAPHY, LIQUID; DESIGNER DRUGS; DRONABINOL; HUMANS; INDOLES; MALE; PSYCHOMOTOR PERFORMANCE; RISK; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84942191886     PISSN: 15389588     EISSN: 1538957X     Source Type: Journal    
DOI: 10.1080/15389588.2015.1018990     Document Type: Article

References (38)

1. P.Adamowicz, D.Zuba, K.Sekuła. Analysis of UR-144 and its pyrolysis product in blood and their metabolites in urine. Forensic Sci Int. 2013;233:320–327.
2. Bluelight. Available at: http://www.bluelight.ru. Accessed September 20, 2014.
3. H.Choi, S.Heo, E.Kim, B.Y.Hwang, C.Lee, J.Lee. Identification of (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl) methanone and its 5-pentyl fluorinated analog in herbal incense seized for drug trafficking. Forensic Toxicol. 2013;31:86–92.
4. H.V.Curran, C.Brignell, S.Fletcher, P.Middleton, J.Henry. Cognitive and subjective dose–response effects of acute oral delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology. 2002;164:61–70.
5. Drugs Forum. Available at: http://www.drugs-forum.com. Accessed September 20, 2014.
6. The European Monitoring Centre for Drugs and Drug Addiction. 2013 Available at: https://ednd.emcdda.europa.eu. Accessed September 20, 2014.
7. J.M.Frost, M.J.Dart, K.R.Tietje, Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem. 2010;53:295–315.
8. 1A receptor activation in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:43–47.
9. A.Grigoryev, P.Kavanagh, A.Melnik, S.Savchuk, A.Simonov. Gas and liquid chromatography–mass spectrometry detection of the urinary metabolites of UR-144 and its major pyrolysis product. J Anal Toxicol. 2013;37:265–276.
10. S.M.R.Gurney, K.S.Scott, S.L.Kacinko, B.C.Presley, B.K.Logan. Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev. 2014;26:54–78. Available at:. http://forend-ex.southernforensic.org/uploads/references/Gurney_et_al-_Pharm_Tox_of_Synthetic_Cannabinoids.pdf. Accessed September 20, 2014.
11. N.Herkenham, A.B.Lynn, M.R.Johnston. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991;11:563–583.
12. M.Hermanns-Clausen, S.Kneisel, M.Hutter, B.Szabo, V.Auwärter. Acute intoxication by synthetic cannabinoids—four case reports. Drug Test Anal. 2013;5:790–794.
13. M.Hermanns-Clausen, S.Kneisel, B.Szabo, V.Auwärter. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013;108:534–544.
14. M.A.Huestis, A.Barnes, M.L.Smith. Estimating the time of last cannabis use from plasma delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol concentrations. Clin Chem. 2005;51:2289–2295.
15. J.W.Huffman, D.Dai. Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg Med Chem Lett. 1994;4:563–566.
16. J.W.Huffman, L.W.Padgett. Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr Med Chem. 2005;12:1395–1411.
17. 9-tetrahydrocannabinol in man. Eur J Pharmacol. 1974;8:172–177.
18. E.L.Karschner, D.M.Schwope, E.W.Schwilke, Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. Drug Alcohol Depend. 2012;125:313–319.
19. P.Kavanagh, A.Grigoryev, S.Savchuk, I.Mikhura, A.Formanovsky. UR-144 in products sold via the Internet: identification of related compounds and characterization of pyrolysis products. Drug Test Anal. 2013;5:683–692.
20. G.F.Kiplinger, J.E.Manno. Dose–response relationships to cannabis in human subjects. Pharmacol Rev. 1971;23:339–347.
21. X.Liao, T.S.Wiedmann. Solubilization of cationic drugs in lung surfactant. Pharm Res. 2000;20:1858–1863.
22. F.Musshoff, B.Madea, G.Kerenbach-Wighton, Driving under the influence of synthetic cannabinoids (“Spice”): a case series. Int J Legal Med. 2014;128:59–64.
23. K.J.Papafotiou, J.D.Carter, C.Stough. The relationship between performance on the Standardised Field Sobriety Tests, driving performance and the level of delta-9 tetrahydrocannabinol (THC) in blood. Forensic Sci Int. 2005;155(2–3):172–178.
24. M.Perez-Reyes, R.E.Hicks, J.Bumberry, A.R.Jeffcoat, C.E.Cook. Interaction between marihuana and ethanol: effects on psychomotor performance. Alcoholism. 1988;12:268–276.
25. C.F.Schaefer, C.G.Gunn, K.M.Dubowski. Dose-related heartrate, perceptual, and decisional changes in man following marijuana smoking. Percept Motor Skills. 1977;44:3–16.
26. N.Schaefer, B.Peters, D.Bregel, A fatal case involving several synthetic cannabinoids. Toxichem Krimtech. 2013;80:248–251.
27. Smoking Blend Reviews. Available at: http://www.smokingblen-dreviews.com/ur-144. Accessed September 20, 2014.
28. Talk Hyperreal. Available at: http://talk.hyperreal.info. Accessed September 20, 2014.
29. The Trip Report. UR-144 Review. Available at: http://the-tripre-port.com/site/tripreport/ur-144-trip-report. Accessed September 20, 2014.
30. K.Tsou, S.Brown, M.C.Sanudo-Pena, K.Mackie, J.M.Walker. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998;83:393–411.
31. N.Uchiyama, M.Kawamura, R.Kikura-Hanajiri, Y.Goda. URB-754: A new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci Int. 2013;227:21–32.
32. U.S. Drug Enforcement Administration. Background information and evaluation of “three factor analysis” (factors 4, 5 and 6) for temporary scheduling. 2013. Available at: http://165.189.64.111/Documents/Board%20Services/Agenda%20Materials/Controlled%20Substanc-es/2013/20130425_agenda_SUA3.pdf. Accessed September 20, 2014.
33. I.Vardakou, C.Pistos, C.SpiliopoulouCh. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett. 2010;197:157–162.
34. T.S.Wiedmann, R.Bhatia, L.W.Wattenberg. Drug solubilisation in lung surfactant. J Control Release. 2000;65:43–47.
35. 9-tetrahydrocannabinol-like effect of tetramethylcyclopropyl ketone indoles. Neuropharmacology. 2013;75:145–154.
36. World Health Organization. UR-144 Critical-Review Report. 2014. Agenda item 4.8. Available at: http://www.who.int/medicines/areas/quality_safety/4_8_Review.pdf. Accessed September 20, 2014.
37. J.K.Yeakel, B.K.Logan. Blood synthetic cannabinoid concentrations in cases of suspected impaired driving. J Anal Toxicol. 2013;37:547–551.
38. 9-THC in normal subjects. Psychopharmacology. 1982;76:245–250.